Ongoing NovoSeven® trials

Intensive Care Medicine, Supplement

Volumn 28, Issue 2, 2002, Pages

  Erhardtsen, Elisabeth ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Bleeding; Haemostasis; NovoSeven; Recombinant activated factor VII (rFVIIa)

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIVITAMIN K; AUTOANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; HEMOSTATIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; WARFARIN; BLOOD CLOTTING FACTOR 7; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; HEMOPHILIA; HEMOSTASIS; HUMAN; INJURY; LIVER DISEASE; LIVER TRANSPLANTATION; PROSTATECTOMY; THROMBOCYTOPATHY; THROMBOCYTOPENIA; TREATMENT OUTCOME; BLOOD CLOTTING DISORDER; REVIEW;

BLOOD COAGULATION DISORDERS; BLOOD LOSS, SURGICAL; CLINICAL TRIALS; FACTOR VII; HEMORRHAGE; HUMANS; RECOMBINANT PROTEINS;

EID: 0036032289     PISSN: 09351701     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Hedner U (1998) Recombinant activated factor VII as a universal haemostatic agent. Blood Coagul Fibrinolysis 9 (Suppl 1):S147-152
2. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE (1984) Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 2:765-768
3. Hedner U, Bergqvist D, Ljungberg J, Nilson B (1985) Haemostatic effect of factor VIIa in thrombocytopenic rabbits. Blood 985 (Suppl 1):1043
4. Brinkhous KM, Hedner U, Garris JB, Diness V, Read MS (1989) Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B and von Willebrand disease. Proc Natl Acad Sci USA 86:1382-1386
5. Monroe DM, Roberts HR, Hoffman M (1994) Platelet procoagulant complex assembly in a tissue factor-initiated system. Br J Haematol 88:364-371
6. Hoffman M, Monroe DM, Oliver JA, Roberts HR (1995) Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood 86:1794-1801
7. Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U (2001) High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 114:114-120
8. Ingerslev J, Freidman D, Gastineau D, Gilchrist G, Johnsson H, Lucas G, McPherson J, Preston E, Scheibel E, Shuman M (1996) Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 26 (Suppl 1):118-123
9. Liebman HA, Chediak J, Fink KI, Galvez AG, Shah PC, Sham RL (2000) Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII. Am J Hematol 63:109-113
10. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E (1998) Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 80:912-918
11. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA (1998) Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 80:773-778
12. Glazer S, Hedner U, Falch JF (1995) Clinical update on the use of recombinant factor VII. Adv Exp Med Biol 386:163-174
13. Lusher JM, Roberts HR, Davignon G, Joist JH, Smith H, Shapiro A, Laurian Y, Kasper CK, Mannucci PM (1998) A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 4:790-798
14. Hedner U, Glazer S, Pingel K, Alberts KA, Blomback M, Schulman S, Johnsson H (1988) Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 2:1193
15. Hedner U, Ingerslev J (1998) Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci 19:163-176
16. Lusher J, Ingerslev J, Roberts H, Hedner U (1998) Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 9:119-128
17. Monroe DM, Hoffman M, Oliver JA, Roberts HR (1997) Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 99:542-547
18. Kjalke M, Monroe DM, Hoffman M, Roberts HR, Hedner U, Ezban M (1999) High-dose factor VIIa restores platelet activation and total thrombin generation in a model system mimicking hemophilia A or B conditions. Blood 94:A451
19. Hedner U, Erhardtsen E (2001) Potential role for rFVIIa in transfusion medicine. Transfusion 42:114-124
20. Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U (1996) Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 26 (Suppl 1):159-164
21. Cosgriff N, Moore EE, Sauaia A, Kenny-Moynihan M, Burch JM, Galloway B (1997) Predicting life-threatening coagulopathy in the massively transfused trauma patient: Hypothermia and acidoses revisited. J Trauma 42:857-861
22. Attar S, Boyd D, Layne E, McLaughlin J, Mansberger AR, Cowley RA (1969) Alterations in coagulation and fibrinolytic mechanisms in acute trauma. J Trauma 9:939-965
23. Martinowitz U, Holcomb JB, Pusateri AE, Stein M, Onaca N, Freidman M, Macaitis JM, Castel D, Hedner U, Hess JR (2001) Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma 50:721-729
24. Friederich PW, Henny CP, Messelink EJ, Breederveld D, Geerdink MGF, Spatoro M, Kurth KK, Buller HR, Levi M (2000) Reduction of Perioperative Blood Loss and Transfusion Requirement in Subjects Undergoing Transabdominal Retropubic Prostatectomy by Administration of Recombinant Activated Factor VII. Friederich PW thesis, Amsterdam University
25. Kenet G, Walden R, Eldad A, Martinowitz U (1999) Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 354:1879
26. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J, Lynn M (2001) Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 51:431-438
27. O'Neill PA, Bluth M, Gloster ES, Wali D, Priovolos S, DiMaio TM, Essex DW, Catanese CA, Strauss RA (2002) Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy. J Trauma 52:400-405
28. Brott T, Broderick J, Kothari R, Barsan W, Tomsick T, Sauerbeck L, Spilker J, Duldner J, Khoury J (1997) Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 28:1-5
29. Fujii Y, Tanaka R, Takeuchi S, Koike T, Minakawa T, Sasaki O (1994) Hematoma enlargement in spontaneous intracerebral hemorrhage. J Neurosurg 80:51-57
30. Fujii Y, Tanaka R (1998) Predictors of hematoma growth? Stroke 29:2442-2443
31. Fujii Y, Takeuchi S, Sasaki O, Minakawa T, Tanaka R (1998) Multivariate analysis of predictors of hematoma enlargement in spontaneous intracerebral hemorrhage. Stroke 29:1160-1166
32. Kazui S, Naritomi H, Yamamoto H, Sawada T, Yamaguchi T (1996) Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course. Stroke 27:1783-1787
33. Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G (1993) Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke 24:987-993
34. Carr JM (1989) Disseminated intravascular coagulation in cirrhosis. Hepatology 10:103-110
35. Paramo JA, Rocha E (1993) Hemostasis in advanced liver disease. Semin Thromb Hemost. 19:184-190
36. Joist JH (1994) Hemostatic abnormalities in liver disease. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Hemostasis and Thrombosis. Lippincott, Philadelphia, pp 906-920
37. Rapaport SI (2000) Coagulation problems in liver disease. Blood Coagul Fibrinolysis 11 (Suppl 1):S69-74
38. Porte RJ, Knot EA, Bontempo FA (1989) Hemostasis in liver transplantation. Gastroenterology 97:488-501
39. Bernstein DE, Jeffers L, Erhardtsen E, Reddy KR, Glazer S, Squiban P, Bech R, Hedner U, Schiff ER (1997) Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: A preliminary study. Gastroenterology 113:1930-1937
40. Jeffers L, Chalasani N, Balart L, Pyrosopoulos N, Erhardtsen E (2002) Safety and Efficacy of Recombinant Factor VIIa in Patients with Liver Disease Undergoing Laparoscopic Liver Biopsy. In press
41. Papatheodoridis GV, Chung S, Keshav S, Pasi J, Burroughs AK (1999) Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis. J Hepatol 31:747-750
42. Hendriks HG, Meijer K, De Wolf JT, Klompmaker IJ, Porte RJ, De Kam PJ, Hagenaars AJ, Melsen T, Slooff MJ, Van der MJ (2001) Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: A pilot study. Transplantation 71:402-405
43. Chuansumrit A, Treepongkaruna S, Phuapradit P (2001) Combined fresh frozen plasma with recombinant factor VIIa in restoring hemostasis for invasive procedures in children with liver diseases. Thromb Haemost 85:748-749
44. Landefeld CS, Goldman L (1989) Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med 87:144-152
45. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD (1995) Bleeding and thromboembolism during anticoagulant therapy: A population-based study in Rochester, Minnesota. Mayo Clin Proc 70:725-733
46. Talstad I (1993) Which coagulation factors interfere with the one-stage prothrombin time? Haemostasis 23:19-25
47. Kyrle PA, Brockmeier J, Weltermann A, Eichinger S, Speiser W, Lechner K, Eichler HG (1997) Inhibition rather than enhancement of hemostatic system activation during initiation of oral anticoagulant treatment. Thromb Haemost 77:685-689
48. Erhardtsen E, Nony P, Dechavanne M, French P, Boissel JP, Hedner U (1998) The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an international normalized ratio above 2.0. Blood Coagul Fibrinolysis 9:741-748
49. Berntorp E, Stigendal L, Lethagen S, Olofsson L, Hedner U (2000) Novo-Seven in warfarin-treated patients. Blood Coagul Fibrinolysis 11 (Suppl 1):S113-S115
50. Deveras RAE, Kessler CM (2000) Recombinant factor VIIa (rFVIIa) successfully and rapidly corrects the excessively high international normalized ratio (INR) and prothrombin times induced by warfarin. Blood 96:A2745
51. Vidarsson B, Onundarson PT (2000) Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost 83:634-635